<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4661">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224015</url>
  </required_header>
  <id_info>
    <org_study_id>191622-104</org_study_id>
    <secondary_id>2010-021271-83</secondary_id>
    <nct_id>NCT01224015</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of botulinum toxin type A compared to
      placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for
      patients who successfully completed Study 191622-099.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
    <description>The investigator assessed the severity of the patient's Crow's Feet Lines at maximum smile using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a score of none or mild at Day 30 is reported.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">684</enrollment>
  <condition>Facial Rhytides</condition>
  <condition>Crow's Feet Lines</condition>
  <condition>Glabellar Lines</condition>
  <arm_group>
    <arm_group_label>onabotulinumtoxinA 24U</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>24 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline (placebo) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onabotulinumtoxinA 44U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.</description>
    <arm_group_label>onabotulinumtoxinA 24U</arm_group_label>
    <arm_group_label>placebo (normal saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>onabotulinumtoxinA 44 U</intervention_name>
    <description>44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.</description>
    <arm_group_label>onabotulinumtoxinA 44U</arm_group_label>
    <other_name>BOTOX®</other_name>
    <other_name>BOTOX® Cosmetic</other_name>
    <other_name>onabotulinumtoxinA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>onabotulinumtoxinA 24 U</intervention_name>
    <description>24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.</description>
    <arm_group_label>onabotulinumtoxinA 24U</arm_group_label>
    <other_name>BOTOX®</other_name>
    <other_name>BOTOX® Cosmetic</other_name>
    <other_name>onabotulinumtoxinA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successfully completed Study 191622-099

        Exclusion Criteria:

          -  Known immunization or hypersensitivity to botulinum toxin of any serotype

          -  Anticipated need for treatment with botulinum toxin of any serotype during the study
             (except for study treatment)

          -  Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral
             sclerosis

          -  Anticipated need for surgery or hospitalization during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antibes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>October 18, 2010</firstreceived_date>
  <firstreceived_results_date>September 27, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Extension study for patients who participated in study 191622-099</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>onabotulinumtoxinA 44U</title>
          <description>44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.</description>
        </group>
        <group group_id="P2">
          <title>onabotulinumtoxinA 24U</title>
          <description>24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Normal Saline)</title>
          <description>Normal Saline injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="361"/>
                <participants group_id="P2" count="227"/>
                <participants group_id="P3" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
                <participants group_id="P2" count="211"/>
                <participants group_id="P3" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>onabotulinumtoxinA 44U</title>
          <description>44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.</description>
        </group>
        <group group_id="B2">
          <title>onabotulinumtoxinA 24U</title>
          <description>24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.</description>
        </group>
        <group group_id="B3">
          <title>Placebo (Normal Saline)</title>
          <description>Normal Saline injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="361"/>
                <measurement group_id="B2" value="227"/>
                <measurement group_id="B3" value="96"/>
                <measurement group_id="B4" value="684"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;45 Years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
                <measurement group_id="B2" value="68"/>
                <measurement group_id="B3" value="33"/>
                <measurement group_id="B4" value="206"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>45 to 65 Years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="241"/>
                <measurement group_id="B2" value="148"/>
                <measurement group_id="B3" value="59"/>
                <measurement group_id="B4" value="448"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;65 Years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="315"/>
                <measurement group_id="B2" value="203"/>
                <measurement group_id="B3" value="80"/>
                <measurement group_id="B4" value="598"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="46"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="16"/>
                <measurement group_id="B4" value="86"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines</title>
        <description>The investigator assessed the severity of the patient's Crow’s Feet Lines at maximum smile using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a score of none or mild at Day 30 is reported.</description>
        <time_frame>Day 30</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants from the Intent-to-treat population, consisting of all randomized participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>onabotulinumtoxinA 44U</title>
            <description>44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.</description>
          </group>
          <group group_id="O2">
            <title>onabotulinumtoxinA 24U</title>
            <description>24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Normal Saline)</title>
            <description>Normal Saline injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="349"/>
                  <measurement group_id="O2" value="223"/>
                  <measurement group_id="O3" value="95"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines</title>
            <description>The investigator assessed the severity of the patient's Crow’s Feet Lines at maximum smile using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a score of none or mild at Day 30 is reported.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="63.6"/>
                  <measurement group_id="O2" value="56.5"/>
                  <measurement group_id="O3" value="1.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety population (all randomized participants who received study drug) was used to calculate the number of participants at risk for Serious Adverse Events and Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>onabotulinumtoxinA 44U</title>
          <description>44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.</description>
        </group>
        <group group_id="E2">
          <title>onabotulinumtoxinA 24U</title>
          <description>24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Normal Saline)</title>
          <description>Normal Saline injected into bilateral Crow’s Feet Line and Frown Line areas per treatment. Patients received up to 2 treatments during the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
